Raras
Buscar doenças, sintomas, genes...
Galactosialidose
ORPHA:351CID-10 · E77.1CID-11 · 5C56.21OMIM 256540DOENÇA RARA

Doença de armazenamento lisossômico caracterizada por características faciais grosseiras, “mancha vermelha cereja” macular e disostose múltipla. A apresentação clínica pode ser heterogênea, variando desde uma forma infantil grave, de início precoce e rapidamente progressiva, até uma forma juvenil/adulta de início tardio e lentamente progressiva.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença de armazenamento lisossômico caracterizada por características faciais grosseiras, “mancha vermelha cereja” macular e disostose múltipla. A apresentação clínica pode ser heterogênea, variando desde uma forma infantil grave, de início precoce e rapidamente progressiva, até uma forma juvenil/adulta de início tardio e lentamente progressiva.

Publicações científicas
260 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
100
pacientes catalogados
Início
All ages
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: E77.1
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (6)
0202010279
Dosagem de aminoácidos (erros inatos)metabolic_test
0202010295
Dosagem de ácidos orgânicos na urinagenetic_test
0202010490
Teste de triagem para erros inatos do metabolismonewborn_screening
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202080013
Teste do pezinho (triagem neonatal)
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
4 sintomas
👁️
Olhos
3 sintomas
🧠
Neurológico
2 sintomas
👂
Ouvidos
1 sintomas
😀
Face
1 sintomas
🛡️
Imunológico
1 sintomas

+ 6 sintomas em outras categorias

Características mais comuns

100%prev.
Deficiência intelectual
Muito frequente (99-80%)
90%prev.
Deficiência auditiva
Muito frequente (99-80%)
90%prev.
Traços faciais grosseiros
Muito frequente (99-80%)
90%prev.
Morfologia vertebral anormal
Muito frequente (99-80%)
90%prev.
Convulsão
Muito frequente (99-80%)
90%prev.
Mancha vermelho-cereja da mácula
Muito frequente (99-80%)
19sintomas
Muito frequente (9)
Ocasional (1)
Sem dados (9)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 19 características clínicas mais associadas, ordenadas por frequência.

Deficiência intelectualIntellectual disability
Muito frequente (99-80%)100%
Deficiência auditivaHearing impairment
Muito frequente (99-80%)90%
Traços faciais grosseirosCoarse facial features
Muito frequente (99-80%)90%
Morfologia vertebral anormalAbnormal vertebral morphology
Muito frequente (99-80%)90%
ConvulsãoSeizure
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico260PubMed
Últimos 10 anos54publicações
Pico20179 papers
Linha do tempo
2026Hoje · 2026🧪 2007Primeiro ensaio clínico📈 2017Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal recessive.

CTSALysosomal protective proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability and activity. This protein is also a carboxypeptidase and can deamidate tachykinins

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
MHC class II antigen presentation
MECANISMO DE DOENÇA

Galactosialidosis

A lysosomal storage disease associated with a combined deficiency of beta-galactosidase and neuraminidase, secondary to a defect in cathepsin A. All patients have clinical manifestations typical of a lysosomal disorder, such as coarse facies, cherry red spots, vertebral changes, foam cells in the bone marrow, and vacuolated lymphocytes. Three phenotypic subtypes are recognized. The early infantile form is associated with fetal hydrops, edema, ascites, visceromegaly, skeletal dysplasia, and early death. The late infantile type is characterized by hepatosplenomegaly, growth retardation, cardiac involvement, and a normal or mildly affected mental state. The juvenile/adult form is characterized by myoclonus, ataxia, angiokeratoma, intellectual disability, neurologic deterioration, absence of visceromegaly, and long survival.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
495.6 TPM
Fibroblastos
285.3 TPM
Aorta
184.8 TPM
Baço
171.4 TPM
Pulmão
166.2 TPM
OUTRAS DOENÇAS (2)
galactosialidosiscathepsin a-related arteriopathy-strokes-leukoencephalopathy
HGNC:9251UniProt:P10619

Variantes genéticas (ClinVar)

112 variantes patogênicas registradas no ClinVar.

🧬 CTSA: NM_000308.4(CTSA):c.1185_1186del (p.Tyr395_Asn396delinsTer) ()
🧬 CTSA: GRCh37/hg19 20q11.21-13.12(chr20:31010829-44560369)x1 ()
🧬 CTSA: NM_000308.4(CTSA):c.254G>C (p.Gly85Ala) ()
🧬 CTSA: NM_000308.4(CTSA):c.54del (p.Leu18_Leu19insTer) ()
🧬 CTSA: NM_000308.4(CTSA):c.1223dup (p.Asp408fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 10 variantes classificadas pelo ClinVar.

9
1
Patogênica (90.0%)
VUS (10.0%)
VARIANTES MAIS SIGNIFICATIVAS
CTSA: NM_000308.4(CTSA):c.777+9C>G [Pathogenic]
CTSA: NM_000308.4(CTSA):c.1357A>G (p.Lys453Glu) [Pathogenic]
CTSA: NM_000308.4(CTSA):c.517_518del (p.Phe173fs) [Pathogenic]
CTSA: NM_000308.4(CTSA):c.1217T>C (p.Met406Thr) [Pathogenic]
CTSA: NM_000308.4(CTSA):c.1315G>A (p.Gly439Ser) [Conflicting classifications of pathogenicity]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Galactosialidose

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

5 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
55 papers (10 anos)
#1

Phenotypic Divergence in Siblings with the Same Genotype: Diffuse Dermal Melanocytosis in Infantile-Onset Galactosialidosis.

Molecular syndromology2025 Oct 16

Galactosialidosis (GS) is an ultra-rare autosomal recessive lysosomal storage disorder caused by pathogenic variants in the CTSA gene. The resulting deficiency of protective protein/cathepsin A leads to reduced β-galactosidase and α-neuraminidase activity, causing multisystem involvement. While typical features include dysmorphic facies, organomegaly, skeletal dysplasia, and neurological impairment, dermatologic manifestations remain poorly characterized. We report a 9-month-old girl presenting with hepatosplenomegaly and diffuse dermal melanocytosis. Her history included nonimmune hydrops fetalis, congenital cataract, developmental delay, and recurrent respiratory infections. Clinical and radiological evaluation revealed coarse facial features, dysostosis multiplex, and periventricular white matter changes. Enzyme assay demonstrated markedly reduced β-galactosidase activity. Genetic testing identified a homozygous CTSA c.359T>C (p.Ile120Thr) variant, classified as likely pathogenic. Family screening revealed her 10-year-old brother carried the same variant in homozygosity. He exhibited milder features, including developmental delay, hearing loss, and skeletal abnormalities without cutaneous involvement or organomegaly. Enzymatic deficiency was confirmed in both siblings. This report highlights diffuse dermal melanocytosis as a possible novel cutaneous marker of GS, potentially aiding early recognition. It also illustrates intrafamilial phenotypic variability despite identical genotypes. Our findings underscore the importance of dermatologic clues in the diagnostic workup of lysosomal storage disorders and advocate for family-based genetic screening to identify asymptomatic or mildly affected individuals.

#2

Juvenile/adult-type galactosialidosis with a homozygous CTSA variant without consanguinity.

Human genome variation2025 Sep 26

Here we report a Japanese patient with juvenile/adult-type galactosialidosis carrying a homozygous c.692+3A>G CTSA variant. Comprehensive genetic analyses including exome sequencing, chromosomal microarray and homozygosity mapping supported biallelic inheritance of this variant and suggested a founder effect in the Japanese population. Clinically, the patient exhibited typical features of the juvenile/adult-type galactosialidosis, with growth impairment noted during adolescence as a less conspicuous but relevant observation.

#3

Novel CTSA Variant Identified in a Thai Family With Late-Infantile Galactosialidosis.

Annals of human genetics2025 May

Galactosialidosis (GS) is a rare lysosomal storage disease (LSD) with variable onset caused by a defect in protective protein/cathepsin A (PPCA) encoded by the CTSA gene. The late-infantile onset is characterized by developmental delay, visceromegaly, coarse facies, and cherry-red macula. We report cases of late-infantile GS in a Thai-Lahu family, with affected members initially presenting with recurrent infections due to T-cell defects. The clinical features of LSD and cherry-red macula led us to perform lysosomal enzyme assays, which showed undetectable activity of PPCA. A novel homozygous missense CTSA variant (NM_000308.4): c.1307A > G (p.Gln436Arg) was identified in affected individuals. In vitro functional analysis suggested that the variant may impair the dimerization process of PPCA, potentially disrupting proper protein maturation or function and leading to significantly reduced PPCA activity. Exome sequencing did not reveal any variants in other genes associated with primary immunodeficiencies. To date, our cases represent the first reported patients with GS and T-cell defects. Our study broadened the clinical and genotype spectrum of this rare disease.

#4

Galactosialidosis: A Report of Three Cases Diagnosed With a Founder Genetic Mutation in the Bahraini Population.

Cureus2025 Jan

Galactosialidosis (GS, OMIM #256540) is a rare metabolic disorder resulting from mutations in the protective protein/cathepsin A (PPCA) or CTSA gene, which is characterized by malfunction of the lysosomal glycoprotein degradation and subsequent intra-lysosomal accumulation of sialyloligosaccharides and glycopeptides. It follows an autosomal recessive inheritance pattern. This systemic disease is characterized by typical clinical features such as short stature, coarse facial features, vertebral deformities, gastrointestinal manifestations, particularly hepatosplenomegaly, cardiac abnormalities, hearing loss, and macular cherry-red spots. GS is classified into three subtypes based on the age of onset and presenting symptoms. The three types include the early infantile (EI) form, which is the most severe; the late infantile form; and the juvenile/adult form. Here, we present three newly diagnosed cases of late-infantile GS in Bahraini patients, all sharing the same previously reported homozygous mutation in the CTSA gene (c.607C>A, p.Pro203Thr), confirmed by targeted mutation analysis. This mutation has been identified in nine Bahraini patients, reflecting a founder effect in the Bahraini population. All three patients presented with coarse facial features, short stature, and poor vision, alongside skeletal deformities. Patient 1 had significant bilateral hip osteoarthritis, while Patient 2. showed lumbar lordosis and extensive bilateral hip avascular necrosis. Patient 3 presented with thoracolumbar levoscoliosis and kyphoscoliosis. Additionally, in Patient 1 and Patient 2 cardiac manifestations were noted, including valvular heart disease. Patient 3 had mild left ventricular hypertrophy (LVH), aortic regurgitation, and mitral regurgitation, along with diffuse angiokeratomas. All patients are currently receiving supportive care and management. This case report highlights the importance of early diagnosis and multidisciplinary care of patients with GS.

#5

Galactosialidosis presenting as non-immune hydrops.

BMJ case reports2024 Oct 01

Hydrops fetalis is an abnormal accumulation of fluid in two or more foetal compartments which is easily detected using prenatal ultrasonography. It can be categorised into immune and non-immune. The non-immune hydrops can result from various aetiologies, including cardiovascular, respiratory, genitourinary infections, chromosomal anomalies and metabolic causes. The metabolic causes, including lysosomal storage disorders (LSD), are increasingly being recognised as the causes of non-immune hydrops. The hydrops fetalis associated with metabolic disorders is usually severe with huge ascites, hepatosplenomegaly, thick skin, renal abnormalities, increased nuchal translucency, renal abnormalities and skeletal deformities. In this report, we describe a case of LSD, that is, galactosialidosis presenting as non-immune hydrops and its diagnosis. In utero diagnosis of the disorder without an index case is challenging. The definitive diagnosis is important for planning and management of future conceptions.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC129 artigos no totalmostrando 54

2025

Phenotypic Divergence in Siblings with the Same Genotype: Diffuse Dermal Melanocytosis in Infantile-Onset Galactosialidosis.

Molecular syndromology
2025

Juvenile/adult-type galactosialidosis with a homozygous CTSA variant without consanguinity.

Human genome variation
2025

Novel CTSA Variant Identified in a Thai Family With Late-Infantile Galactosialidosis.

Annals of human genetics
2025

Galactosialidosis: A Report of Three Cases Diagnosed With a Founder Genetic Mutation in the Bahraini Population.

Cureus
2024

Galactosialidosis presenting as non-immune hydrops.

BMJ case reports
2024

Neuraminidase-1 (NEU1): Biological Roles and Therapeutic Relevance in Human Disease.

Current issues in molecular biology
2023

Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.

Glycoconjugate journal
2023

The development of a broad-spectrum retaining β-exo-galactosidase activity-based probe.

Organic &amp; biomolecular chemistry
2023

Structure of the immunoregulatory sialidase NEU1.

Science advances
2023

Analysis of urinary oligosaccharide excretion patterns by UHPLC/HRAM mass spectrometry for screening of lysosomal storage disorders.

Journal of inherited metabolic disease
2022

Clinical spectrum and outcome of nine patients with a novel genetic variant of galactosialidosis in the Kingdom of Bahrain.

JIMD reports
2022

Reversal of neuroinflammation in novel GS model mice by single i.c.v. administration of CHO-derived rhCTSA precursor protein.

Molecular therapy. Methods &amp; clinical development
2021

The rare reason of pain in hip girdle: Mucolipidosis type 3 gamma.

The Turkish journal of pediatrics
2021

AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study.

Molecular therapy. Methods &amp; clinical development
2021

Inflammatory arthritis complicating galactosialidosis: a case report.

BMC rheumatology
2023

Infantile Galactosialidosis with Novel Mutation: An Early Presentation.

Journal of pediatric genetics
2021

Lysosomal storage disorders as an etiology of nonimmune hydrops fetalis: A systematic review.

Clinical genetics
2021

Structure of the murine lysosomal multienzyme complex core.

Science advances
2021

Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.

Molecular therapy. Methods &amp; clinical development
2020

Gastrointestinal stromal tumor in perforated Meckel's diverticulum: a case report and literature review.

Surgical case reports
2020

Galactosialidosis Type IIb with Bilateral Macular Cherry-Red Spots but Mild Dysfunction.

Case reports in ophthalmology
2021

A sialidosis type I cohort and a quantitative approach to multimodal ophthalmic imaging of the macular cherry-red spot.

The British journal of ophthalmology
2020

Placental Findings in Lysosomal Storage Disease Diagnosis: A Case Report of Galactosialidosis.

Case reports in pathology
2020

The Role of Hematopoietic Cell Transplant in the Glycoprotein Diseases.

Cells
2020

Propionic acidemia: an extremely rare cause of hemophagocytic lymphohistiocytosis in an infant.

Archivos argentinos de pediatria
2020

Loss of kidney function due to proteinuria, common problem with a rare cause: Answer.

Pediatric nephrology (Berlin, Germany)
2020

Lysosomal storage disease spectrum in nonimmune hydrops fetalis: a retrospective case control study.

Prenatal diagnosis
2019

Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content.

Scientific reports
2019

A new heterozygous compound mutation in the CTSA gene in galactosialidosis.

Human genome variation
2019

Quantitative natural history characterization in a cohort of 142 published cases of patients with galactosialidosis-A cross-sectional study.

Journal of inherited metabolic disease
2019

Clinical implementation of gene panel testing for lysosomal storage diseases.

Molecular genetics &amp; genomic medicine
2018

UPLC-MS/MS Analysis of Urinary Free Oligosaccharides for Lysosomal Storage Diseases: Diagnosis and Potential Treatment Monitoring.

Clinical chemistry
2018

Use of modified U1 small nuclear RNA for rescue from exon 7 skipping caused by 5'-splice site mutation of human cathepsin A gene.

Gene
2018

New CTSA mutation in early infantile galactosialidosis.

Pediatrics international : official journal of the Japan Pediatric Society
2018

[Development of Enzyme Drugs Derived from Transgenic Silkworms to Treat Lysosomal Diseases].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
2017

Galactosialidosis in a Newborn with a Novel Mutation in the CTSA Gene Presenting with Transient Hyperparathyroidism.

Balkan journal of medical genetics : BJMG
2018

Dental Management of a Young Child Affected by Galactosialidosis and a Gigantic Abdominal Growth.

Case reports in dentistry
2018

Turning the backbone into an ankylosed concrete-like structure: Case report.

Medicine
2018

Secondary Hemophagocytic Syndrome Associated with COG6 Gene Defect: Report and Review.

JIMD reports
2018

[Galactosialidosis: a new "de novo" mutation in CTSA gene in a patient with late infantile galactosialidosis].

Archivos argentinos de pediatria
2018

Inborn errors of metabolism in a cohort of pregnancies with non-immune hydrops fetalis: a single center experience.

Journal of perinatal medicine
2017

LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease.

PloS one
2017

Galactosialidosis: historic aspects and overview of investigated and emerging treatment options.

Expert opinion on orphan drugs
2017

A Turkish case of galactosialidosis with a new homozygous mutation in CTSA gene.

Metabolic brain disease
2017

Development of a new tandem mass spectrometry method for urine and amniotic fluid screening of oligosaccharidoses.

Rapid communications in mass spectrometry : RCM
2017

Mice with Catalytically Inactive Cathepsin A Display Neurobehavioral Alterations.

Behavioural neurology
2017

Multigene panel next generation sequencing in a patient with cherry red macular spot: Identification of two novel mutations in NEU1 gene causing sialidosis type I associated with mild to unspecific biochemical and enzymatic findings.

Molecular genetics and metabolism reports
2017

Inherited diseases caused by mutations in cathepsin protease genes.

The FEBS journal
2016

Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL).

Neurology
2016

An Unusual Case of LCHAD Deficiency Presenting With a Clinical Picture of Hemophagocytic Lymphohistiocytosis: Secondary HLH or Coincidence?

Journal of pediatric hematology/oncology
2017

Measurement of Elevated Concentrations of Urine Keratan Sulfate by UPLC-MSMS in Lysosomal Storage Disorders (LSDs): Comparison of Urine Keratan Sulfate Levels in MPS IVA Versus Other LSDs.

JIMD reports
2016

Lysosomal localization of Japanese medaka (Oryzias latipes) Neu1 sialidase and its highly conserved enzymatic profiles with human.

Gene
2016

Chemical chaperone treatment for galactosialidosis: Effect of NOEV on β-galactosidase activities in fibroblasts.

Brain &amp; development
2015

Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis.

Expert opinion on orphan drugs
Ver todos os 129 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Galactosialidose.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Galactosialidose

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Phenotypic Divergence in Siblings with the Same Genotype: Diffuse Dermal Melanocytosis in Infantile-Onset Galactosialidosis.
    Molecular syndromology· 2025· PMID 41409303mais citado
  2. Juvenile/adult-type galactosialidosis with a homozygous CTSA variant without consanguinity.
    Human genome variation· 2025· PMID 41006206mais citado
  3. Novel CTSA Variant Identified in a Thai Family With Late-Infantile Galactosialidosis.
    Annals of human genetics· 2025· PMID 40165614mais citado
  4. Galactosialidosis: A Report of Three Cases Diagnosed With a Founder Genetic Mutation in the Bahraini Population.
    Cureus· 2025· PMID 39981487mais citado
  5. Galactosialidosis presenting as non-immune hydrops.
    BMJ case reports· 2024· PMID 39353673mais citado
  6. Lysosomal Neuraminidase 1 (NEU1): Its Unique Molecular Characters and Therapeutic Approaches for Deficiencies.
    Adv Exp Med Biol· 2026· PMID 41917397recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:351(Orphanet)
  2. OMIM OMIM:256540(OMIM)
  3. MONDO:0009737(MONDO)
  4. GARD:3953(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q1491661(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Galactosialidose
Compêndio · Raras BR

Galactosialidose

ORPHA:351 · MONDO:0009737
Prevalência
Unknown
Casos
100 casos conhecidos
Herança
Autosomal recessive
CID-10
E77.1 · Defeitos na degradação das glicoproteínas
CID-11
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0268233
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades